New Trial Suggests CV Benefit With EPA: RESPECT-EPA

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.
Medscape Medical News

source https://www.medscape.com/viewarticle/983621?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.